DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Gleevec (Imatinib Mesylate) - Published Studies

 
 



Gleevec Related Published Studies

Well-designed clinical trials related to Gleevec (Imatinib)

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. [2011.09]

Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases. [2011.07]

Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review. [2011.05.01]

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. [2011.04.20]

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. [2011.02.15]

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. [2011.02.01]

Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. [2011]

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. [2010.12.23]

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). [2010.11.11]

Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. [2010.11.01]

Imatinib: as adjuvant therapy for gastrointestinal stromal tumour. [2010.10.22]

Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. [2010.10]

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. [2010.10]

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. [2010.08.15]

Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence. [2010.08]

Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. [2010.08]

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. [2010.06.17]

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. [2010.06.17]

High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study. [2010.06]

Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review. [2010.05]

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. [2010.03.15]

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. [2010.03.11]

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. [2010.03]

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. [2010.02]

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. [2010.02]

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. [2010.01.20]

Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. [2010]

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. [2010]

High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. [2009.12]

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. [2009.10]

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). [2009.09.15]

Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. [2009.08.20]

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. [2009.07.01]

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. [2009.07]

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. [2009.06.18]

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. [2009.06]

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. [2009.05.07]

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. [2009.05.07]

A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. [2009.04]

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. [2009.03.28]

Effect of antacid on imatinib absorption. [2009.02]

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. [2009.02]

Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. [2009.01.20]

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. [2008.11.20]

Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. [2008.09]

Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial. [2008.06]

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. [2008.02.01]

BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. [2007.12.01]

CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. [2007.12]

Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. [2007.09]

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. [2007.06.15]

Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). [2007.05.15]

The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice. [2007.04]

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. [2007.03.20]

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. [2007.03.01]

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. [2006.12.07]

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. [2006.10.14]

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. [2006.10.10]

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. [2006.05]

The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. [2006.02.28]

A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. [2005.12.06]

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. [2005.08.20]

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. [2005.08]

Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. [2005.07]

Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. [2004.10]

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. [2004.09.25]

Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. [2004.05]

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. [2004.04.15]

Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. [2004.02]

Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. [2004.01.01]

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. [2003.12.01]

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. [2003.12]

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. [2003.12]

Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec. [2003.11]

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. [2003.10.09]

Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. [2003.08.23]

Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. [2003.06.01]

[Morphology of gastrointestinal stromal tumors in advanced stages of the disease: baseline findings before chemotherapy with imatinib] [2003.06]

Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. [2003.06]

Quality of life on imatinib. [2003.04]

Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. [2003.04]

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. [2003.03.13]

Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. [2003]

Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). [2002.10]

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. [2002.08.15]

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. [2001.10.27]

Well-designed clinical trials possibly related to Gleevec (Imatinib)

Regorafenib in gastrointestinal stromal tumors. [2014]

[Treatment of pulmonary fibrosis : New substances and new interventions.] [2011.11.19]

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. [2011.06]

Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. [2011.05]

Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. [2011.04.15]

Nilotinib: evaluation and analysis of its role in chronic myeloid leukemia. [2011.02]

Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects. [2011]

Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis. [2010.11]

Current strategies in the management of hypereosinophilic syndrome, including mepolizumab. [2010.08]

Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. [2010.02]

Future treatments in systemic sclerosis. [2010.01]

Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. [2010]

Future treatments in systemic sclerosis. [2010]

Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. [2009.04]

The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: The example of sunitinib for gastrointestinal stromal tumour. [2008.05]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017